Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evonik Invests $108M in Vancouver GMP Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Evonik Invests $108M in Vancouver GMP Facility

New site will expand lipid-based drug delivery manufacturing capacity.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Editor’s Take: British Columbia is home to a fast-growing life sciences sector, where more than 2,000 companies employ close to 20,000 people, most of them in Greater Vancouver.

Evonik is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada, which will increase Evonik’s development and manufacturing capacity, helping pharmaceutical and biotech customers bring lipid-based pharmaceutical products from development through commercial scale.

Evonik’s total investment of over 150 million CAD ($108 million) in Vancouver is supported by the Canadian federal government’s Strategic Response Fund with up to 68 million CAD ($49 million). Drug product production is planned to begin at the end of 2029.

“Lipid-based drug delivery technologies are already enabling the next generation of medicines. With the support of the Canadian federal government, this investment builds on our long-standing expertise in the field, enabling the development and commercialization of more life-changing therapies,” said Lauren Kjeldsen, member of Evonik’s Executive Board and COO for the Custom Solutions segment at Evonik.

The project will expand Evonik’s existing manufacturing capabilities through the establishment of a modern GMP facility with more than three times the manufacturing capacity of the current facility for advanced pharmaceutical products. The new facility will also significantly advance quality control (QC) and microbiological testing capabilities, improving efficiency and supporting the timely release of products for clinical use.

More Evonik News

Earlier this year, Evonik announced a $100 million investment over five years to modernize its Lafayette (Tippecanoe), Indiana API manufacturing facility. The company is also investing about EUR 80 million at its Fermas site in Slovenská Ľupča to add downstream fermentation technology.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics